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Biology of local heat therapy for cancer
Charles F. Babbs, M.D., Ph.D.
Biomedical Engineering Center, Purdue University, West Lafayette, Indiana, USA.
Abstract
Successful cancer therapy must selectively destroy tumor tissue while sparing the host's normal
tissues. Local heat treatment can have such a selective effect because abnormalities in tumor
blood vessels supply less oxygen to heat-stressed tumor cells and are less efficient in cooling
tumor tissue by blood perfusion.
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[MEDICAL INSTRUMENTATION 1982; 16(1):23-26]
Heat therapy for cancer dates back to ancient times, when physicians as notable as Hippocrates
and Galen used hot irons to destroy fungating cancers (Stonn et al. 1980). In the past decade
numerous reports of the antitumor effects of heat in a variety of animal models, and in man, have
kindled a renaissance of interest in hyperthermia therapy. Clinical studies from several
institutions suggest that a significant number of tumors unresponsive to conventional radiation or
chemotherapy have shown dramatic responses to heat, either alone (Crile 1962; LeVeen et al.
1976; Storm et al. 1979; LeVeen et al. 1980) or in combination with radiation (Hornback et al.
1977; Hahn and Kim 1980; U et al., in press).
Crile, for example, provided anecdotal reports of regressions of squamous cell carcinomas,
neuroblastomas, and metastatic melanomas after the tumor-bearing member was immersed in a
46-47 oC water bath. LeVecn and coworkers reported substantial regressions in 21 patients with
a variety of carcinomas after local heating with radiofrequcncy current. Hornback and associates
pursued the combination of microwave-induced hyperthermia and ionizing radiation in 21
patients with far-advanced, histologically proven malignancies that were considered to be
refractory to further medical treatment. Complete regression occurred in 16 of the patients, and 9
of the 16 were free of disease at 9 months. Although not strictly controlled clinical trials, these
studies seem to indicate that hyperthermic therapy is quite effective in many patients whose
cancers most certainly would have continued to spread without treatment and who, in the opinion
of their physicians, would have had a poor response to further conventional therapy.
There are probably several reasons for the delayed rediscovery of heat therapy. Technically,
there have been and still are practical difficulties with apparatus for heating. Hot wax baths,
hyperthermic arterial perfusion, radiofrequency waves, microwaves, high-intensity ultrasound,
and whole-body hyperthermia (fever therapy) have been tried. None has been developed to an
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entirely satisfactory state, although gradual progress is being made. There are also difficulties
with clinical thermometry--i.e., the process of recording the temperature distribution in and
around the treated tumor (Cetas and Connor 1978). At present, most heat therapy centers rely on
needle-like probes (thermistors or thermocouples mounted on needles) to measure temperatures
at a few selected points in the treatment field, which must be assumed to be representative. These
technical limitations have made it difficult to perform local heat therapy well. However, the most
important reason why heat therapy has not been accepted until recently has been the lack of a
physiologic rationale for its selective action against tumor cells and tissues.
Ideally, heat therapy must destroy cancer cells without affecting nearby normal cells, in much the
same way that modern antibiotics destroy bacteria without damaging the host. Bacteria can be
selectively destroyed by antibiotics because their cell walls, protein synthesizing apparatus, or
chromosomes are chemically different from mammalian cells. The corresponding chemical
differences between cancer cells and normal cells are much more subtle, and have proved elusive
targets for selective therapeutic action without toxicity. However, several lines of evidence are
beginning to develop that explain why tumor tissue may be especially vulnerable to local heat
treatment. These include evidence of the metabolic deficiencies of cancer cells, which seem to
produce selective heat sensitivity, coupled with an abnormal pattern of blood vessels in many
tumors, which tends to limit blood flow. The abnormally reduced perfusion of tumor tissues
delivers less oxygen than the tumor cells require when their metabolism is raised at higher
temperatures. Moreover, the reduced blood flow in the tumor tends to carry away heat less
rapidly from the tumor tissue than from adjacent normal tissues. As a result, the tumor tissue
reaches higher steady-state temperature; thus multiplying the selective effects of heat on
individual tumor cells. This double-edged sword, in principle, provides a significant therapeutic
lever for the selective destruction of tumor tissue.
Normal vs. Neoplasic Cells In Vitro
Cell culture studies suggest that malignant cells may be slightly more heat sensitive than their
(normal) tissues of origin (Mondovi et al. 1969; Giovanella et al. 1973; Cavaliere et al. 1967;
Muckle and Dickson 1971). For example, Mondovi and coworkers found that exposure of
hepatoma cells to an aerobic environment at 43 °C caused inhibition of oxygen uptake, while
normal regenerating liver cells were not affected. Muckle and Dickson found that 42 oC
hyperthermia decreased oxygen uptake and viability of rabbit VX2 carcinoma cells while normal
rabbit kidney, liver, and red blood cells were unaffected by the elevated temperature.
There are several possible explanations for such results. A relative lack of membrane repair
enzymes or DNA repair enzymes, or both, in the abnormal tumor cells might mean thermal
damage accumulates faster. A relative lack of ATP-generating enzymes might mean the cells are
unable to meet the metabolic demands of higher temperatures. Whatever may be the critical
cellular differences, they seem to account for the occasional success of whole-body hyperthermia
(fever therapy) in producing remissions of cancer. Recently, investigators at the Universities of
Edinburgh, New Mexico, and Mississippi have reported favorable responses, including tumor
necrosis or regression, in patients maintained at 41-42 oC for several hours (Storm et al. 1981).
Even greater anatomic and physiologic differences seem to exist between normal and neoplastic
tissues than between isolated normal and neoplastic cells. These differences provide a specific
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rationale for local heat therapy--i.e., application of energy only to the tumor-bearing region in
such a way that core body temperature remains dose to normal.
Normal vs. Neoplastic Tissues In Vivo
Solid tumor masses in vivo seem even more heat sensitive than cells from the same tumor line
grown in vitro (Song, in press; Kang et al., in press; Song et al. 1981). When grown in tissue
culture, normal and neoplastic cells look much the same under the microscope. However, in vivo
tumor tissues are recognizably different from their normal tissues of origin. The tumor cells are
typically packed together in disorganized clusters, and perhaps more important, the blood vessels
nourishing them are subtly abnormal in character. Instead of the usual distribution of small
arteries, capillaries, and small veins, there seems to be a predominance of sinusoidal capillary
beds in most solid tumors. These capillary sinusoids are broader and longer, and are separated by
larger intercapillary distances than are normal capillaries (Folkman 1976; Ide et al. 1939; Vaupel
1977; Intanglietta et al. 1977). Because blood flow in tumor capillaries is more sluggish than that
in normal capillaries (lntaglietta), oxygen delivery to tumor tissues is far from optimal.
Recent work by Folkman (1976) has shown that tumor blood vessels are formed in response to a
chemical tumor angiogenesis factor (TAF) liberated by tumor cells. TAF seems to stimulate the
growth of capillaries, but not to stimulate the development of these capillary sprouts into welldifferentiated, larger caliber arterioles. Consequently, the density of arteries and arterioles in
many tumor tissues is abnormally small in relation to the venous vasculature (Intaglietta; Endrich
et al. 1979; Gross 1979). The arterial vessels, found near the tumor surface, seem to be preexistent and do not proliferate as the tumor grows (Peterson 1979). These arterioles tend to be
pushed aside as the tumor expands, and their capacity to supply blood to the tumor capillaries
becomes limited. They exhibit little vasomotion (Goodall et al. 1965) and seem to be already
maximally dilated during tumor growth (Song; Gross). This general pattern of tumor vascularity
has been observed in a variety of systems, including rat myelosarcoma (Habighorst 1977),
transplanted Brown-Pearce rabbit epithelioma (Ide et al.), hamster malignant neurilemoma (Eddy
and Casarett 1973), and rat BA 1112 sarcoma implants (Gross).
The abnormal vascular pattern of tumors tends more often than not to produce relatively poor
blood flow, as measured in milliliters per minute per gram of tissue (Peterson). Moreover, the
abnormal tumor vessels seem unable to increase perfusion in response to the metabolic stress
imposed by heat. For example, Storm and coworkers (1979) and Song have shown that blood
flow to larger tumor masses does not increase when the tumor tissues are heated, although blood
flow in heated normal tissues does increase. This physiologic vasodilation of normal tissues, in
response to heat, increases blood cooling to prevent excessive temperature rise. Tumor tissues,
on the other hand, may be quite limited in their ability to increase heat dissipation by augmenting
blood flow, simply because the tumor vessels are relatively lacking in smooth muscle capable of
dilating in response to local needs.
It is easy to summarize the abnormal character of tumor blood vessels by means of the electrical
analogy in Fig. 1. Distribution of blood flow between normal tissues and tumor tissue depends
upon regional vascular resistance. Vascular resistance in normal tissues is variable and subject to
manipulation by drugs and metabolites that act upon vascular smooth muscle. Vascular
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resistance in tumor tissue tends to remain constant. The heart feeds the parallel normal and tumor
tissue beds. During local heat therapy dilation of the normal vessels will create an effective
arteriovenous shunt around the tumor. Such changes in the distribution of blood flow would
enhance cooling of normal tissues and simultaneously reduce cooling of the tumor to produce
actual selective heating. As described previously (Babbs and DeWitt 1981), larger tumors are
especially vulnerable to such selective heating effects because of limits imposed by the physical
processes of heat transfer.

Fig. 1. Electrical analogy of blood flow in normal and neoplastic tissues. Variable
resistor R1 = normally reactive arterioles; fixed resistor R2 = tumor vessels. Series
resistance R3 = resistance of arterioles that branch to feed both tumors and normal
vessels.
Furthermore, reduced blood flow in tumors during that therapy has important biochemical
effects. Hypoxia and the resultant anerobic metabolism and lactic acidosis make the tumor tissue
in the heated region even more vulnerable to thermal injury. Such potentiating of thermal injury
by hypoxia and acidosis has been shown quite clearly both in vitro and in vivo (Gerweck and
Rollinger 1976; Dewey and Freeman 1980; Song). Thus, because of the vascular abnormalities
of tumor tissue, larger tumor masses can be raised to higher temperatures than surrounding
normal tissues, and they are biochemically more heat sensitive.
Exploitation of Vascular Abnormalities
Our own group is actively pursuing the enhancement of local heat therapy with vasodilators,
which are drugs that act directly or indirectly to relax vascular smooth muscle. They enhance
regional blood flow when given in moderate doses by causing dilation of normal resistance
vessels (arterioles). Since tumor vessels tend to be lacking in smooth muscle, such drugs should
have a selective effect on normal tissues that would significantly improve local heat therapy for
cancer. Indeed, the selective ineffectiveness of vasodilators on tumor vessels is becoming an
established fact.
In the experimental literature, Kruuv and coworkers (1967) have reported that the vasodilators
chlorpromazine, isoproterenol, or inhaled amyl nitrite, which are known to increase blood flow
in normal tissues, actually decreased blood flow in mammary tumors--a finding consistent with
4

the conceptual model of Fig. 1 and with previous observations that smooth muscle is relatively
lacking in the microvasculature of tumors. In human patients, Jonsson and associates (1978)
studied the effects of intra-arterial prostaglandin E1 , a potent vasodilator, as an adjuvant to
angiography of tumors of the extremities in 10 cases. Except in one case, involving an
hemangioma, the visualization of tumor vessels and delineation of the extent of disease were
worse after the use of prostaglandin E1, whereas visualization of small normal muscular arteries
improved. Evidently, prostaglandin increased blood flow in normal tissues relative to the tumor
in a manner that would be quite helpful in improving the selectivity of local heat therapy.
In our own laboratories we have been investigating the use of the vasodilator, hydralazine, for
improving the selective heating of transplantable venereal tumors in dogs. Fig. 2 shows the
results of a typical experiment in which blood flow to the tumor and underlying normal tissue
samples was measured with radioactive microspheres at roughly 10-min intervals. Before
hydralazine was injected intravenously (0.5 mg/kg), the tumor had a slightly greater level of
perfusion than the surrounding normal tissue. Hydralazine increased tissue perfusion in the
normal tissue samples fivefold. At the same time, perfusion of the tumor tissue dropped nearly
fivefold. Indeed, the vasodilator actually caused a reversal in the ratio of tumor to normal tissue
perfusion. We have now performed more than six experiments of this type with similar results.

Fig. 2. Regional blood flow in a dog with transmissible venereal tumor before (trials 1
and 2) and after (trials 3 and 4) administration of hydralazine (arrow). Dashed line
indicates tumor flow. Solid line indicates flow in normal muscle underlying the tumor.
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Fig. 3 shows the temperatures measured during vasodilator-enhanced tumor heating in one of
these dogs. The tumor-bearing region of one hindlimb was heated by passing 13.56 MHz
radiofrequency current, generated by a diathermy unit (Birtcher Corp., El Monte CA), through a
Helmholtz coil that encompassed the limb. The plots show center tumor temperature and
subjacent normal tissue temperature as a function of time. The normal tissue (muscle) was
exposed to essentially the same field strength as the tumor. Records demonstrate a dramatic
increase in the tumor temperature during inductive heating with minimal increase in normal
tissue temperature following hydralazine pretreatment. The position of the heating coils
remained the same, but we were able to increase the intensity and duration of heating after the
hydralazine injection, while keeping the normal tissue temperature  40 °C. Note that prior to
drug treatment, normal tissue temperature was slightly greater than tumor temperature.
Hydralazine reversed this state of affairs; tumor temperature reached 48-50 °C, at which level a
treatment time of less than 15 min can be expected to cause irreversible cellular injury (Babbs
and DeWitt; Dickson and Calderwood 1980; Henle and Dethlefsen 1980). Encouraged, we are
now beginning trials of vasodilator-enhanced selective heat therapy in dogs with spontaneous
tumors of the extremities.

Fig. 3. Temperature time curves for transmissible venereal tumor and underlying
normal muscle in a dog during local inductive heat therapy. Left: temperature records
for heating trial before hydralazine injection. Right: temperature records after the
hydralazine injection.
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Biologic Limitations of Local Heat Therapy
For the reasons just discussed, local heat therapy has significant potential for selectively
destroying tumor tissue in a particular location. However, like radiation, local heating will never
be a cure for widespread metastatic disease. Moreover, it remains to be seen whether heat
therapy can be made consistently effective in destroying all the tumor tissue at a given site. In
theory, spherical tumors may be heated effectively, if one is willing to accept damage to a thin
shell of surrounding normal tissue (Babbs and DeWitt). Irregularly shaped tumor masses,
however, may be much more difficult to heat uniformly.
Viable cells remaining near the tumor edge may require follow-up radiation or chemotherapy. In
addition, certain areas may be off-limits to heat therapy. The eyes, for example, contain vitreous
humor, which is devoid of blood flow and so would be heated as efficiently as the most poorly
perfused tumor. Moreover, there may be certain tumor types, such as hemangiomas, that have
blood flow much greater than most normal tissues; thus they might never be treated effectively
by local heat.
Nonetheless, as more is learned about the biologic rationale for heat treatment of cancer and as
instrumentation for heating and thermometry improve, it is likely that heat will become a
standard therapeutic modality in selected patients with certain types of tumors. At present, all
forms of hyperthermia are experimental, and this modality should not be used in lieu of standard
forms of effective cancer therapy. The challenge for the biomedical engineer in the future will be
to design selective heat therapy of cancer, so that someday it will become routine, safe, and
effective treatment for well-defined groups of patients.
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